Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL-Reference-Cited by-同舟云学术

Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL

Published:2024-04-26 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Gritti Giuseppe^ORCID,Ferrari Silvia,Lussana Federico,Barbui Anna Maria,Landi Francesco,Rondi Monica,Putelli Alessandro,Ballardini Francesco,Quaresmini Giulia,Paganessi Muriel,Pavoni Chiara,Ghirardi Arianna,Gotti Elisa,Capelli Chiara,Golay Josée,Introna Martino,Rambaldi Alessandro

Funder

Regione Lombardia

Associazione Italiana per la Ricerca sul Cancro

Amgen (Thousand Oaks, CA) Fondazione per la Ricerca Ospedale Maggiore

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01057-z.pdf

Reference15 articles.

1. Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2017;53:70–78.

2. Flinn IW, Van Der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood. 2014;123:2944–52.

3. Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy. Leukemia. 2010;24:1310–6.

4. Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5:e362–2.

5. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells. 2000;18:10–18.